<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03423537</url>
  </required_header>
  <id_info>
    <org_study_id>hCG-GR-001-2016</org_study_id>
    <secondary_id>2016-005208-24</secondary_id>
    <nct_id>NCT03423537</nct_id>
  </id_info>
  <brief_title>Low-dose HCG as an Adjunct to Ovarian Stimulation in Subfertile Women Undergoing ART</brief_title>
  <acronym>HCG</acronym>
  <official_title>A Prospective, Multicenter, Double-blind, Placebo-controlled, Phase III Clinical Study, on the Efficacy and Safety of Low-dose hCG in a Short Protocol With GnRH Agonist and Ovarian Stimulation With Recombinant FSH (rFSH) During the Follicular Phase in Subfertile Women Undergoing ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this prospective randomized clinical trial is to investigate whether the
      addition of low-dose hCG to a short GnRH-agonist protocol for IVF and ovarian stimulation
      with rFSH from the onset of the follicular phase and throughout stimulation in sub fertile
      women undergoing IVF, improves pregnancy rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized, double-blind, placebo-controlled, two
      parallel group of patients, Phase IIIb clinical study to test the efficacy and safety of
      adding low-dose hCGs in a short protocol with GnRH agonist and ovarian stimulation with
      recombinant FSH (rFSH) from the onset of the follicular phase and throughout the duration of
      stimulation in enrolled women to the increase in the rate of clinical pregnancies.

      Main end point will be the rate of clinical pregnancy (positive heart rate at 7 weeks of
      gestation in the ultrasound), while secondary endpoints will be

        -  The number of follicles (&gt; 11,&gt; 14,&gt; 18 mm) on the day of triggering with hCG

        -  The thickness of the endometrium on the day of follicular maturation

        -  Live birth rates

        -  Automatic abortion rates (loss of pregnancy after positive heart function up to 20 weeks
           of gestation)

        -  The rate of ongoing pregnancy (positive heart function after 12 weeks of gestation),

        -  The percentage of ovarian hyperstimulation syndrome (after triggering) with hCG for the
           next 2 weeks

        -  The rate of multiple pregnancy.

      Participants will be randomly divided into two groups: the intervention group (Group 1) and
      the control group (Group 2). Randomization will be done using sealed envelopes marked &quot;Group
      1&quot; and &quot;Group 2&quot;. The randomization list will be prepared centrally for the four
      participating clinics (research centers) and there will be a &quot;stratification&quot; per center, per
      30, respectively, and will be shared among the participants.

      &quot;Group 1&quot; will indicate the application of the protocol by adding hCG with the initiation of
      controlled ovarian stimulation protocol for IVF / ICSI with rFSH, and &quot;Group 2&quot; will indicate
      the application of the conventional protocol without the addition of hCG .

      Each patient's assignment to a treatment group will be made by calling the unit's midwife who
      will have 2 envelopes with the above indications and who will not be present when the pair is
      informed by 2 members of the research team.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of clinical pregnancy</measure>
    <time_frame>7 weeks after the initiation of treatment</time_frame>
    <description>Positive heart rate at 7 weeks of gestation in ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of follicles</measure>
    <time_frame>2 weeks after the initiation of treatment</time_frame>
    <description>(&gt; 11,&gt; 14,&gt; 18 mm) on the day of triggering with hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The thickness of the endometrium</measure>
    <time_frame>2 weeks after the initiation of treatment</time_frame>
    <description>On the day of follicular maturation (triggering) with hCG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rates</measure>
    <time_frame>After the 20th week after the initiation of treatment, in case of pregnancy</time_frame>
    <description>Birth after the 20th week of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Automatic abortion rates - miscarriage</measure>
    <time_frame>up to 20 weeks of gestation</time_frame>
    <description>(Lss of pregnancy after positive heart function up to 20 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of ovarian hyperstimulation syndrome</measure>
    <time_frame>2 weeks after the hCG triggering</time_frame>
    <description>After triggering with hCG</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>HCG; IVF; Pregnancy Rates; ART; Chorionic Gonadotropin</condition>
  <arm_group>
    <arm_group_label>Group 1 [HCG (+) group]</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Group 1&quot; will indicate the application of the protocol by adding hCG with the initiation of standard GnRH agonist protocol for IVF / ICSI with rFSH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 [placebo]</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>&quot;Group 2&quot; will indicate the application of the standard GnRH agonist protocol without the addition of hCG, but placebo, instead</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hCG</intervention_name>
    <description>the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.</description>
    <arm_group_label>Group 1 [HCG (+) group]</arm_group_label>
    <other_name>Pregnyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100IU per day containing N/S 0.9% will be injected</description>
    <arm_group_label>Group 2 [placebo]</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: between 35 and 40 years of age,

          2. Physiological menstrual cycles (24-35 day cycle),

          3. Normal endocrine function (normal PRL and TSH, FSH ≤ 15 IU / ml),

          4. Transvaginal ultrasound (TVS) without pathological findings,

          5. Free personal medical history,

          6. Indication for IVF / ICSI (NICE, 2016)

          7. 1st or 2nd IVF / ICSI cycle

        Exclusion Criteria:

          1. Endocrine or metabolic disorders, e.g. PCO (S)

          2. Pathology of the uterus and / or endometrium,

          3. Pelvic inflammatory disease (PID),

          4. Basal FSH levels&gt; 15 IU / ml,

          5. Surgery in the ovaries,

          6. Body Mass Index (BMI) ≥ 35 kg / m2,

          7. Age: &lt;35 years &amp;&gt; 40 years old
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charalampos Siristatidis, Ass Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siristatidis</last_name>
    <phone>5822237</phone>
    <phone_ext>0030 210</phone_ext>
    <email>harrysiri@yahoo.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>3rd Department of Obstetrics and Gynecology, Assisted Reproduction Unit</name>
      <address>
        <city>Athens</city>
        <state>Chaidari</state>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charalampos Siristatidis, Ass Prof</last_name>
      <phone>5832283</phone>
      <phone_ext>0030 210</phone_ext>
      <email>harrysiri@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Petros Drakakis, Ass Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Konstantinos Dafopoulos, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Efstratios Kolibianakis, Ass Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Basil Tarlatzis, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://www.nice.org.uk/guidance/cg156</url>
    <description>Current guidelines</description>
  </link>
  <results_reference>
    <citation>Drakakis P, Loutradis D, Beloukas A, Sypsa V, Anastasiadou V, Kalofolias G, Arabatzi H, Kiapekou E, Stefanidis K, Paraskevis D, Makrigiannakis A, Hatzakis A, Antsaklis A. Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation. Reprod Biol Endocrinol. 2009 Oct 13;7:110. doi: 10.1186/1477-7827-7-110.</citation>
    <PMID>19825188</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomaa H, Casper RF, Esfandiari N, Chang P, Bentov Y. Addition of low dose hCG to rFSh benefits older women during ovarian stimulation for IVF. Reprod Biol Endocrinol. 2012 Aug 6;10:55. doi: 10.1186/1477-7827-10-55.</citation>
    <PMID>22866896</PMID>
  </results_reference>
  <results_reference>
    <citation>Martins WP, Vieira AD, Figueiredo JB, Nastri CO. FSH replaced by low-dose hCG in the late follicular phase versus continued FSH for assisted reproductive techniques. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD010042. doi: 10.1002/14651858.CD010042.pub2. Review.</citation>
    <PMID>23543584</PMID>
  </results_reference>
  <results_reference>
    <citation>Beretsos P, Partsinevelos GA, Arabatzi E, Drakakis P, Mavrogianni D, Anagnostou E, Stefanidis K, Antsaklis A, Loutradis D. &quot;hCG priming&quot; effect in controlled ovarian stimulation through a long protocol. Reprod Biol Endocrinol. 2009 Aug 31;7:91. doi: 10.1186/1477-7827-7-91.</citation>
    <PMID>19719843</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>February 3, 2018</last_update_submitted>
  <last_update_submitted_qc>February 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Siristatidis Charalampos, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor in Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

